– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

– PharmCADD announced that it has finished USD 16m series B funding on March 31, 2021.
– This funding round was led by Strategic Investors: Huons, Samyang Holdings and SD BIOSENSOR; and Financial Investors: KTB Network, Daily Partners, DSC Investment, KDB Capital, Maple Investment and KB Securities.
– As a result, PharmCADD has secured total of USD 22m in funding since its establishment.
– PharmCADD plans to use the funding not only to launch the U.S. and India-based branches but also to advance its AI & Physics-based drug discovery platform technology, Pharmulator™, and to expand R&D manpower. The funding will be used for the preclinical study of internal pipelines as well.